Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis

Nadera J. Sweiss, Imre Noth, Mehdi Mirsaeidi, Wei Zhang, Edward T. Naureckas, D. Kyle Hogarth, Mary Strek, Philip Caligiuri, RobertoF Machado, TimothyB Niewold, Joe G N Garcia, Aileen L. Pangan, Robert P. Baughman

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis. Methods: An open-label, single-center study was conducted in 11 patients with refractory pulmonary sarcoidosis. Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up atWeek 52. The primary endpoint was the percent change in predicted forced vital capacity (FVC) at 24 weeks. Secondary efficacy parameters included the 6-minute walk test (6MWT), Borg dyspnea score, and Physician's (PGA) and Patient's (PaGA) Global Assessments. A successful outcome of the study was defined as reduction in immunosuppressive therapy (prednisone to 10 mg or less), improvement in FVC of 5% or greater, improvement in 6-minute walk test distance (6MWD) of 50 meter or greater at the end of weeks 24 and 52. Results: Eleven patients received adalimumab and had 24-week follow-ups.Only ten patients had a Week 52 evaluation. FVC stabilized in seven patients, and four patients showed improvement in FVC. Five patients had improved 6MWD, and nine had lower Borg dyspnea scores. PGA and PaGA improved at weeks 24 and 52 for all patients (P<0.008 for all comparisons). Among 11 patients who underwent adalimumab treatment, 9 (82%) and 8 (80%) had a successful outcome at the end of 24 and 52 weeks respectively. No severe adverse incidents were reported. Conclusions: In this small, open-label study, adalimumab improved refractory pulmonary sarcoidosis and was well tolerated (ClinicalTrials.gov identifier NCT00311246).

Original languageEnglish (US)
Pages (from-to)46-54
Number of pages9
JournalSarcoidosis Vasculitis and Diffuse Lung Diseases
Volume31
Issue number1
StatePublished - 2014

Fingerprint

Sarcoidosis
Vital Capacity
Pulmonary Sarcoidosis
Prostaglandins A
Therapeutics
Dyspnea
Adalimumab
Immunosuppressive Agents
Prednisone
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Outcome Assessment (Health Care)
Physicians

Keywords

  • Adalimumab
  • Anti-TNF-α antibody
  • Pulmonary sarcoidosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Internal Medicine

Cite this

Sweiss, N. J., Noth, I., Mirsaeidi, M., Zhang, W., Naureckas, E. T., Hogarth, D. K., ... Baughman, R. P. (2014). Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 31(1), 46-54.

Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. / Sweiss, Nadera J.; Noth, Imre; Mirsaeidi, Mehdi; Zhang, Wei; Naureckas, Edward T.; Hogarth, D. Kyle; Strek, Mary; Caligiuri, Philip; Machado, RobertoF; Niewold, TimothyB; Garcia, Joe G N; Pangan, Aileen L.; Baughman, Robert P.

In: Sarcoidosis Vasculitis and Diffuse Lung Diseases, Vol. 31, No. 1, 2014, p. 46-54.

Research output: Contribution to journalArticle

Sweiss, NJ, Noth, I, Mirsaeidi, M, Zhang, W, Naureckas, ET, Hogarth, DK, Strek, M, Caligiuri, P, Machado, R, Niewold, T, Garcia, JGN, Pangan, AL & Baughman, RP 2014, 'Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis', Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 31, no. 1, pp. 46-54.
Sweiss NJ, Noth I, Mirsaeidi M, Zhang W, Naureckas ET, Hogarth DK et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2014;31(1):46-54.
Sweiss, Nadera J. ; Noth, Imre ; Mirsaeidi, Mehdi ; Zhang, Wei ; Naureckas, Edward T. ; Hogarth, D. Kyle ; Strek, Mary ; Caligiuri, Philip ; Machado, RobertoF ; Niewold, TimothyB ; Garcia, Joe G N ; Pangan, Aileen L. ; Baughman, Robert P. / Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. In: Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2014 ; Vol. 31, No. 1. pp. 46-54.
@article{1d36029b467f485f968585d50ae73a43,
title = "Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis",
abstract = "Background: Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis. Methods: An open-label, single-center study was conducted in 11 patients with refractory pulmonary sarcoidosis. Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up atWeek 52. The primary endpoint was the percent change in predicted forced vital capacity (FVC) at 24 weeks. Secondary efficacy parameters included the 6-minute walk test (6MWT), Borg dyspnea score, and Physician's (PGA) and Patient's (PaGA) Global Assessments. A successful outcome of the study was defined as reduction in immunosuppressive therapy (prednisone to 10 mg or less), improvement in FVC of 5{\%} or greater, improvement in 6-minute walk test distance (6MWD) of 50 meter or greater at the end of weeks 24 and 52. Results: Eleven patients received adalimumab and had 24-week follow-ups.Only ten patients had a Week 52 evaluation. FVC stabilized in seven patients, and four patients showed improvement in FVC. Five patients had improved 6MWD, and nine had lower Borg dyspnea scores. PGA and PaGA improved at weeks 24 and 52 for all patients (P<0.008 for all comparisons). Among 11 patients who underwent adalimumab treatment, 9 (82{\%}) and 8 (80{\%}) had a successful outcome at the end of 24 and 52 weeks respectively. No severe adverse incidents were reported. Conclusions: In this small, open-label study, adalimumab improved refractory pulmonary sarcoidosis and was well tolerated (ClinicalTrials.gov identifier NCT00311246).",
keywords = "Adalimumab, Anti-TNF-α antibody, Pulmonary sarcoidosis",
author = "Sweiss, {Nadera J.} and Imre Noth and Mehdi Mirsaeidi and Wei Zhang and Naureckas, {Edward T.} and Hogarth, {D. Kyle} and Mary Strek and Philip Caligiuri and RobertoF Machado and TimothyB Niewold and Garcia, {Joe G N} and Pangan, {Aileen L.} and Baughman, {Robert P.}",
year = "2014",
language = "English (US)",
volume = "31",
pages = "46--54",
journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",
issn = "1124-0490",
publisher = "Mattioli 1885 S.p.A.",
number = "1",

}

TY - JOUR

T1 - Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis

AU - Sweiss, Nadera J.

AU - Noth, Imre

AU - Mirsaeidi, Mehdi

AU - Zhang, Wei

AU - Naureckas, Edward T.

AU - Hogarth, D. Kyle

AU - Strek, Mary

AU - Caligiuri, Philip

AU - Machado, RobertoF

AU - Niewold, TimothyB

AU - Garcia, Joe G N

AU - Pangan, Aileen L.

AU - Baughman, Robert P.

PY - 2014

Y1 - 2014

N2 - Background: Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis. Methods: An open-label, single-center study was conducted in 11 patients with refractory pulmonary sarcoidosis. Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up atWeek 52. The primary endpoint was the percent change in predicted forced vital capacity (FVC) at 24 weeks. Secondary efficacy parameters included the 6-minute walk test (6MWT), Borg dyspnea score, and Physician's (PGA) and Patient's (PaGA) Global Assessments. A successful outcome of the study was defined as reduction in immunosuppressive therapy (prednisone to 10 mg or less), improvement in FVC of 5% or greater, improvement in 6-minute walk test distance (6MWD) of 50 meter or greater at the end of weeks 24 and 52. Results: Eleven patients received adalimumab and had 24-week follow-ups.Only ten patients had a Week 52 evaluation. FVC stabilized in seven patients, and four patients showed improvement in FVC. Five patients had improved 6MWD, and nine had lower Borg dyspnea scores. PGA and PaGA improved at weeks 24 and 52 for all patients (P<0.008 for all comparisons). Among 11 patients who underwent adalimumab treatment, 9 (82%) and 8 (80%) had a successful outcome at the end of 24 and 52 weeks respectively. No severe adverse incidents were reported. Conclusions: In this small, open-label study, adalimumab improved refractory pulmonary sarcoidosis and was well tolerated (ClinicalTrials.gov identifier NCT00311246).

AB - Background: Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis. Methods: An open-label, single-center study was conducted in 11 patients with refractory pulmonary sarcoidosis. Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up atWeek 52. The primary endpoint was the percent change in predicted forced vital capacity (FVC) at 24 weeks. Secondary efficacy parameters included the 6-minute walk test (6MWT), Borg dyspnea score, and Physician's (PGA) and Patient's (PaGA) Global Assessments. A successful outcome of the study was defined as reduction in immunosuppressive therapy (prednisone to 10 mg or less), improvement in FVC of 5% or greater, improvement in 6-minute walk test distance (6MWD) of 50 meter or greater at the end of weeks 24 and 52. Results: Eleven patients received adalimumab and had 24-week follow-ups.Only ten patients had a Week 52 evaluation. FVC stabilized in seven patients, and four patients showed improvement in FVC. Five patients had improved 6MWD, and nine had lower Borg dyspnea scores. PGA and PaGA improved at weeks 24 and 52 for all patients (P<0.008 for all comparisons). Among 11 patients who underwent adalimumab treatment, 9 (82%) and 8 (80%) had a successful outcome at the end of 24 and 52 weeks respectively. No severe adverse incidents were reported. Conclusions: In this small, open-label study, adalimumab improved refractory pulmonary sarcoidosis and was well tolerated (ClinicalTrials.gov identifier NCT00311246).

KW - Adalimumab

KW - Anti-TNF-α antibody

KW - Pulmonary sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=84900564369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900564369&partnerID=8YFLogxK

M3 - Article

C2 - 24751453

AN - SCOPUS:84900564369

VL - 31

SP - 46

EP - 54

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

SN - 1124-0490

IS - 1

ER -